Sone-026 ((full)) Instant

Phase I dose‑escalation (N = 48) in relapsed/refractory B‑cell malignancies identified 75 mg qd as the recommended phase II dose (RP2D) based on pharmacodynamic (pAKT↓ > 80 %) and safety data (no grade ≥ 3 infections, neutropenia ≤ 20 %). Preliminary efficacy (overall response rate, ORR = 48 %; complete response, CR = 12 %) compared favorably with idelalisib (ORR ≈ 45 %).

She placed her hand on the cool metal. Instantly, a flood of images and sounds cascaded through her mind: SONE-026

Close-ups and lighting designed to emphasize Yua's facial features and skin. Phase I dose‑escalation (N = 48) in relapsed/refractory

Is "SONE-026" a: